These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 37104299)

  • 1. SARS-CoV-2 infection- induced seroprevalence among children and associated risk factors during the pre- and omicron-dominant wave, from January 2021 through December 2022, Thailand: A longitudinal study.
    Suntronwong N; Vichaiwattana P; Klinfueng S; Puenpa J; Kanokudom S; Assawakosri S; Chansaenroj J; Srimuan D; Thatsanatorn T; Songtaisarana S; Sudhinaraset N; Wanlapakorn N; Poovorawan Y
    PLoS One; 2023; 18(4):e0279147. PubMed ID: 37104299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SARS-CoV-2 Infection-and mRNA Vaccine-induced Humoral Immunity among Schoolchildren in Hawassa, Ethiopia.
    Merid Y; Tekleselasie W; Tesfaye E; Gadisa A; Fentahun D; Abate A; Alemu A; Mihret A; Mulu A; Gelanew T
    Front Immunol; 2023; 14():1163688. PubMed ID: 37398668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Immunity and Covid-19 Severity with Omicron Variant in South Africa.
    Madhi SA; Kwatra G; Myers JE; Jassat W; Dhar N; Mukendi CK; Nana AJ; Blumberg L; Welch R; Ngorima-Mabhena N; Mutevedzi PC
    N Engl J Med; 2022 Apr; 386(14):1314-1326. PubMed ID: 35196424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
    Tsang NNY; So HC; Cowling BJ; Leung GM; Ip DKM
    Lancet Infect Dis; 2023 Apr; 23(4):421-434. PubMed ID: 36521506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seroprevalence of SARS-CoV-2 anti-nucleocapsid total Ig, anti-RBD IgG antibodies, and infection in Thailand: a cross-sectional survey from October 2022 to January 2023.
    Chansaenroj J; Suntronwong N; Kanokudom S; Assawakosri S; Vichaiwattana P; Klinfueng S; Wongsrisang L; Thongmee T; Aeemjinda R; Khanarat N; Srimuan D; Thatsanathorn T; Yorsaeng R; Katanyutanon A; Thanasopon W; Bhunyakitikorn W; Sonthichai C; Angsuwatcharakorn P; Withaksabut W; Wanlapakorn N; Sudhinaraset N; Poovorawan Y
    Sci Rep; 2023 Sep; 13(1):15595. PubMed ID: 37730917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased breadth and neutralization of antibodies against SARS-CoV-2 variants after infection and vaccination: A serosurveillance study in pediatric patients of Southern Switzerland.
    Mazzara C; Bassi J; Silacci-Fregni C; Muoio F; Passini N; Corti D; Simonetti GD; Vanoni F; Kottanattu L; Piccoli L
    Eur J Pediatr; 2024 Mar; 183(3):1425-1434. PubMed ID: 38175262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.
    Poon RW; Chan BP; Chan WM; Fong CH; Zhang X; Lu L; Chen LL; Lam JY; Cheng VC; Wong SSY; Kok KH; Yuen KY; To KK
    Emerg Microbes Infect; 2022 Dec; 11(1):2116-2119. PubMed ID: 35880656
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SARS-CoV-2 seroprevalence in Portugal following the third epidemic wave: results of the second National Serological Survey (ISN2COVID-19).
    Kislaya I; Gonçalves P; Gómez V; Gaio V; Roquette R; Barreto M; Sousa-Uva M; Torres AR; Santos J; Matos R; Manita C; Almeida Santos J; Soeiro S; de Sousa R; Costa I; Verdasca N; Guiomar R; Rodrigues AP;
    Infect Dis (Lond); 2022 Jun; 54(6):418-424. PubMed ID: 35023439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron B.1.1.529 variant infections associated with severe disease are uncommon in a COVID-19 under-vaccinated, high SARS-CoV-2 seroprevalence population in Malawi.
    Mseka UL; Mandolo J; Nyoni K; Divala O; Kambalame D; Mapemba D; Kamzati M; Chibwe I; Henrion MYR; Manda K; Thindwa D; Mvula M; Odala B; Kamng'ona R; Dzinza N; Jere KC; Feasey N; Ho A; Amoah AS; Gordon M; Swarthout TD; Crampin A; Heyderman RS; Kagoli M; Chitsa-Banda E; Mitambo C; Phuka J; Chilima B; Kasambara W; Jambo KC; Chauma-Mwale A
    EClinicalMedicine; 2023 Feb; 56():101800. PubMed ID: 36600885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 seroprevalence among children in Greece during Omicron variant period.
    Dimopoulou D; Sotiri D; Kousi D; Loulou G; Raptaki K; Neofytou A; Dasoula F; Tampouratzi M; Koloi A; Eleftheriou E; Vergadi E; Papadimitriou E; Zorbadaki I; Mavridi A; Miliordos K; Steletou E; Strempela M; Fragkou PC; Spoulou V; Michos A; Gkentzi D; Papaevangelou V; Ladomenou F; Grivea I; Syrogiannopoulos G; Galanakis E; Zaoutis T; Tryfinopoulou K; Tsolia MN
    Eur J Pediatr; 2024 May; 183(5):2491-2499. PubMed ID: 38478132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prevalence of antibodies against SARS-CoV-2 in the Norwegian population, August 2021.
    Tunheim G; Rø GØI; Chopra A; Aase A; Kran AB; Vaage JT; Lund-Johansen F; Hungnes O
    Influenza Other Respir Viruses; 2022 Nov; 16(6):1004-1013. PubMed ID: 35770841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimated BNT162b2 Vaccine Effectiveness Against Infection With Delta and Omicron Variants Among US Children 5 to 11 Years of Age.
    Khan FL; Nguyen JL; Singh TG; Puzniak LA; Wiemken TL; Schrecker JP; Taitel MS; Zamparo JM; Jodar L; McLaughlin JM
    JAMA Netw Open; 2022 Dec; 5(12):e2246915. PubMed ID: 36515946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal change in SARS-CoV-2 seroprevalence in 3-to 16-year-old children: The Augsburg Plus study.
    Leone V; Meisinger C; Temizel S; Kling E; Gerstlauer M; Frühwald MC; Burkhardt K
    PLoS One; 2022; 17(8):e0272874. PubMed ID: 35951611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world serological responses to extended-interval and heterologous COVID-19 mRNA vaccination in frail, older people (UNCoVER): an interim report from a prospective observational cohort study.
    Vinh DC; Gouin JP; Cruz-Santiago D; Canac-Marquis M; Bernier S; Bobeuf F; Sengupta A; Brassard JP; Guerra A; Dziarmaga R; Perez A; Sun Y; Li Y; Roussel L; Langelier MJ; Ke D; Arnold C; Whelan M; Pelchat M; Langlois MA; Zhang X; Mazer BD;
    Lancet Healthy Longev; 2022 Mar; 3(3):e166-e175. PubMed ID: 35224524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
    Scaggs Huang F
    J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of SARS-CoV-2-specific anti-spike IgM, IgG, and anti-nucleocapsid IgG antibodies during the second wave of the pandemic: A population-based cross-sectional survey across Kashmir, India.
    Lone KS; Khan SMS; Qurieshi MA; Majid S; Pandit MI; Haq I; Ahmad J; Bhat AA; Bashir K; Bilquees S; Fazili AB; Hassan M; Jan Y; Kaul RR; Khan ZA; Mushtaq B; Nazir F; Qureshi UA; Raja MW; Rasool M; Asma A; Bhat AA; Chowdri IN; Ismail S; Jeelani A; Kawoosa MF; Khan MA; Khan MS; Kousar R; Lone AA; Nabi S; Qazi TB; Rather RH; Sabah I; Sumji IA
    Front Public Health; 2022; 10():967447. PubMed ID: 36276377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population-Weighted Seroprevalence From Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection, Vaccination, and Hybrid Immunity Among US Blood Donations From January to December 2021.
    Busch MP; Stramer SL; Stone M; Yu EA; Grebe E; Notari E; Saa P; Ferg R; Manrique IM; Weil N; Fink RV; Levy ME; Green V; Cyrus S; Williamson PC; Haynes J; Groves J; Krysztof D; Custer B; Kleinman S; Biggerstaff BJ; Opsomer JD; Jones JM
    Clin Infect Dis; 2022 Oct; 75(Suppl 2):S254-S263. PubMed ID: 35684973
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study.
    Zaballa ME; Perez-Saez J; de Mestral C; Pullen N; Lamour J; Turelli P; Raclot C; Baysson H; Pennacchio F; Villers J; Duc J; Richard V; Dumont R; Semaani C; Loizeau AJ; Graindorge C; Lorthe E; Balavoine JF; Pittet D; Schibler M; Vuilleumier N; Chappuis F; Kherad O; Azman AS; Posfay-Barbe KM; Kaiser L; Trono D; Stringhini S; Guessous I;
    Lancet Reg Health Eur; 2023 Jan; 24():100547. PubMed ID: 36474728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody response and risk of reinfection over 2 years among the patients with first wave of COVID-19.
    Peghin M; De Martino M; Palese A; Chiappinotto S; Fonda F; Gerussi V; Sartor A; Curcio F; Grossi PA; Isola M; Tascini C
    Clin Microbiol Infect; 2024 Apr; 30(4):522-530. PubMed ID: 38141821
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Post-vaccination SARS-CoV-2 seroprevalence in children aged 3-11 years and the positivity in unvaccinated children: A retrospective, single-center study.
    Li J; Ge M; Dai S; Song Q; Liu W; Wang Y; Xu W; Ma L
    Front Immunol; 2022; 13():1030238. PubMed ID: 36420275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.